Citations

Clear

40 citation(s) found for "Lester, Scott".

Impact of COVID-19 on Multidisciplinary Lymphoma Tumor Boards: An Analysis of Practice and Care Changes
Okcu, Izel, Khurana, Arushi , Levy, Robert J. , Delaune, Robert, Larson, Daniel P. , Witzig, T. E., Howard, Matthew T., Wiseman, Gregory A., Comfere, Nneka I. , Shah, Namrata, Breitkreutz, Lawrence R., Bold, Mike S., Lunn, Brendan, Breen, William G. , Kimball, Valerie M., Nedved, Adrienne, Lentz, Ruth A., King, Rebecca L., Okcu, Izel , Durani, Urshila , Levy, Robert J., Moustafa, Muhamad Alhaj , Rosenthal, Allison , Iqbal, Madiha , Bold, Mike S., Wang, Yucai , Lester, Scott C. , Hoppe, Bradford S. , Hill, Caroline R., Habermann, Thomas M.

Mayo Clinic

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 2283-2283

10.1182/blood-2024-210539 Get It

Introduction: Outcomes from multidisciplinary lymphoma tumor boards in the molecular era are limited, and the effects of transitioning to virtual formats during the COVID-19 pandemic are not well-documented. This study evaluates how the transition of the Mayo Clinic Lymphoma Tumor Board to a virtual format has impacted its effectiveness and operations. The board, part of the International Mayo Clinic Care Network (MCCN), involves case presentations, subspecialist reviews, and collaborative recommendations. Methods: The Mayo Clinic Lymphoma Tumor Board, an integral part of the Mayo Clinic Care Network (MCCN), conducted a comprehensive review of lymphoma cases from 2014 to 2024. The board's review process involves a structured approach including the presentation of clinical case details, radiology and hematopathology findings, proposed treatment options, relevant literature review, and discussions. From 2014 to 2024, the Mayo Clinic Lymphoma Tumor Board reviewed a total of 722 patients. The review process involves a multidisciplinary team, including physicians, pharmacists, clinical research associates, and trainees. Recommendations and changes related to radiology interpretation, pathologic diagnosis, and treatment approaches were documented and tracked prospectively. In March 2020, the board transitioned to a virtual format due to the COVID-19 pandemic. This shift allowed for remote participation and continued collaborative review while maintaining the board's structured approach and documentation practices. Results: In a total of 722 patients, changes in care were identified in 423 patients, including 287 with newly diagnosed lymphoma and 136 with relapse or refractory disease. Among those who experienced changes, 94 had diffuse large B-cell lymphoma, 49 had follicular lymphoma, 39 had marginal zone lymphoma, 36 had classical Hodgkin lymphoma, and 29 had mantle cell lymphoma. Prior to the COVID-19 pandemic, 431 patients were analyzed, with 217 (50.3%) experiencing changes. A total of 268 changes were documented among these patients. Changes in radiologic interpretation occurred in 9 patients (2.1% of 431 total patients). Pathologic diagnosis changes were noted in 42 patients (9.7%). Additional testing was recommended for 73 patients (16.9%), and clinical management was altered for 144 patients (33.4%). After transitioning to a virtual format, 291 patients were reviewed post-COVID, with 206 (70.8%) having recommended changes. The total number of change recommendations was 322, reflecting increases across all components compared to previous data, with adjustments for varying numbers of patients reviewed. Specifically, radiologic interpretation changes occurred in 21 patients (7.2%), pathologic diagnosis changes in 57 patients (19.6%), additional testing recommendations for 85 patients (29.2%), and clinical management alterations in 159 patients (54.7%). Conclusion: Transitioning to a virtual format in the Mayo Clinic Lymphoma Tumor Board's continued to demonstrate the effectiveness, with increased changes in diagnostic interpretations and clinical management. These results illustrate the potential of virtual tumor boards to improve collaborative decision-making and adapt to evolving clinical needs.
Reduction of soluble PD-L1 by plasma exchange and radiation therapy in patients with refractory melanoma re-sensitizes to immunotherapy.
Orme, Jacob J. , Lingamaneni, Prashanth, Lavoie, Roxane R. , Hirdler, Jacob, Bering, Elizabeth A., Gicobi, Joanina K. , Hsu, Michelle A. , Dale, Heather, Kottschade, Lisa A. , Block, Matthew S. , Markovic, Svetomir, Olivier, Ken, Owen, Dawn , Dronca, Roxana , Packard, Annie T. , Zhang, Henan , Kim, Yohan , Dorr, Maddy, Dizona, Paul, Hirdler, Jacob B. , Hsu, Michelle, Dale, Heather, Childs, Daniel S. , McWilliams, Robert R. , Mansfield, Aaron S. , Markovic, Svetomir N. , Lester, Scott C. , Daniel, J. , Dong, Haidong , Lucien, Fabrice , Winters, Jeffrey L. , Park, Sean S.

Mayo Clinic

No container title available | October 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4542220/v1 Get It

Abstract Introduction: Immune checkpoint inhibitors (ICI) are an essential systemic therapy for advanced melanoma. However, most melanomas develop resistance to ICI. Tumor-derived soluble PD-L1 (sPD-L1) and other soluble immunosuppressive factors drive checkpoint inhibitor resistance and correlate with inferior survival. We previously showed that therapeutic plasma exchange (TPE) removes sPD-L1 from circulation. Thus, we hypothesized that TPE-mediated removal of sPD-L1 and other immunosuppressive factors could overcome immunotherapy resistance in refractory melanoma. Methods: In this clinical trial (NCT04581382), we prospectively enrolled eighteen (18) patients with widely metastatic melanoma with progression despite anti-PD-1 ICI and elevated sPD-L1 by ELISA (≥1.7ng/mL). Each patient received radiotherapy to between one and three metastatic lesions (at least two unirradiated lesions) followed by three TPE sessions on consecutive days and re-challenge with checkpoint inhibitor. The primary safety and efficacy endpoints of the study were adverse events (AEs) and sPD-L1 reduction by TPE, respectively. Secondary endpoints included RECIST-based response in unirradiated lesions and overall survival. Correlative studies included kinetics of sPD-L1 and soluble immonsuppressive factors and dynamics of peripheral immune cell phenotypes. Results: Mean age was 62 (SD 13) and seven of eighteen (39%) were female. Mean baseline sPD-L1 was 26.31 ng/mL (40.01). The treatment was well-tolerated with one (6%) patient with grade 3 and 4 adverse events from a central line infection after TPE. Levels of sPD-L1 were significantly reduced by TPE (mean 80.2% reduction, p<0.0001). Two patients (11.1%) experienced complete response (CR), one (5.6%) partial response, three (16.7%) stable disease, and 12 (66.7%) progressive disease. In one case, immunotherapy was discontinued after two years due to no detectable lesions. Changes in tumor-reactive (TTR) GZMB+/CX3CR1+/CD11ahigh and other peripheral immune cell populations predicted overall survival in this cohort. In addition to sPD-L1, other soluble mediators of ICI resistance were also reduced by TPE and predicted overall survival in this cohort. Summary/Conclusion: sPD-L1 and other soluble immunoregulatory signaling molecules are important mediators of ICI resistance. SBRT and TPE can resensitize ICI-refractory melanoma by removing these factors. Patients with persistently elevated or rapid rebound of sPD-L1 following TPE experienced poor response and overall survival. Serial monitoring of sPD-L1 may predict response to ICI and multiple courses of TPE may be necessary. Our findings may apply in other ICI-resistant cancers with elevated sPD-L1. ClinicalTrials.gov registration: NCT04581382, ReCIPE-M1 (Rescuing Cancer Immunotherapy with Plasma Exchange in Melanoma 1).
Cancer in Patients With Incidental Asymmetric Oropharynx Positron Emission Tomography Uptake
Armstrong, Michael , O’Byrne, Thomas J., Gottlich, Harrison C. , Tasche, Kendall K. , Moore, Eric J. , Gamez, Mauricio E. , Neben-Wittich, M.A. , Price, Katharine A., Lowe, Val J. , Abel, Kathryn M. Van , O'Byrne, Thomas J, Gamez, Mauricio , Lester, Scott C. , Neben-Wittich, Michelle A, Van Abel, Kathryn M , Burkett, Brian J. , Yin, Linda X. , Price, Daniel L. , Routman, David M. , Daniel, J.

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | August 29, 2024 | Volume: 150 | Issue: 12 | Pages: 1078

10.1001/jamaoto.2024.2556 | PMID 39207815 Get It

ImportanceAsymmetric oropharynx uptake on positron emission tomography (PET)/computed tomography (CT) is a common incidental finding and often prompts otolaryngology referral to rule out malignancy; however, the true risk of malignancy based on this finding is unknown.ObjectiveTo identify the incidence of oropharynx cancer in patients with incidental asymmetric oropharynx PET uptake.Design, Setting, and ParticipantsIn this retrospective cohort study, patients 18 years and older undergoing PET/CT scans at Mayo Clinic between January 2001 and December 2018 were included. Patients with a history or pretest suspicion of oropharynx cancer were excluded. Data were analyzed from March 2021 to December 2023.ExposureBlinded radiologic review of imaging studies, including measurement of maximum standardized uptake values (SUVmax) of the ipsilateral side of concern and contralateral side. Retrospective medical record review for associated clinical data.Main Outcomes and MeasuresThe primary study outcome was the incidence of oropharynx cancer diagnosis in patients with asymmetric oropharynx PET uptake. The primary outcome was formulated before data collection.ResultsOf the 1854 patients identified with asymmetric oropharynx PET uptake, 327 (17.6%) met inclusion criteria. Of these, 173 (52.9%) were male, and the median (range) age was 65.0 (24.8-90.7) years. The mean (SD) follow-up interval was 52.1 (43.4) months. A total of 18 of 327 patients (5.5%) were newly diagnosed with oropharynx cancer. The most common diagnosis was squamous cell carcinoma (n = 9), followed by lymphoma (n = 8), and sarcoma (n = 1). Patients with an incidental diagnosis of oropharynx cancer had higher mean (SD) ipsilateral SUVmax (8.7 [3.7] vs 5.3 [1.9]) and SUVmax ratio (3.0 [1.6] vs 1.6 [0.6]) compared with patients with normal examination findings. SUVmax ratio and difference were found to be good discriminators of oropharynx cancer, with areas under the receiver operating characteristic curve of 86.3% (95% CI, 76.4-94.6) and 85.8% (95% CI, 74.8-94.6), respectively. Patients with a new diagnosis of oropharynx cancer were more likely to have a corresponding CT abnormality than those with normal examination findings (6 of 18 [33%] vs 24 of 295 [8.1%]). Patients with concerning lesions on oropharynx palpation by an otolaryngology health care professional were significantly more likely to be diagnosed with oropharynx cancer compared with patients with normal examination findings (odds ratio, 28.4; 95% CI, 6.6-145.8).Conclusions and RelevanceIn this cohort study, while incidental asymmetric oropharynx PET uptake was common, a new diagnosis of oropharynx cancer was not and potentially results in a large volume of unnecessary referrals and work-up. Using SUVmax ratio, SUVmax difference, and CT correlation may increase the benefit of referral. Patients with a palpable oropharynx lesion and asymmetric oropharynx PET uptake should undergo confirmatory biopsy.
Outcomes of patients with R/R B-cell NHL and limited (
Saifi, Omran , Breen, William G. , Rule, William G., Stish, Bradley J. , Bansal, Radhika , Hathcock, Matthew , Johnston, Patrick B. , Ansell, Stephen M. , Khurana, Arushi , Ayala, Ernesto , Kharfan‐Dabaja, Mohamed A. , Peterson, Jennifer , Lester, Scott C. , Bansal, Radhika , Paludo, Jonas , Villasboas, Jose Caetano , Wang, Yucai , Moustafa, Muhamad Alhaj , Murthy, Hemant S , Kharfan-Dabaja, Mohamed A , Hoppe, Bradford S , Peterson, Jennifer L , Rosenthal, Allison , Muñoz, Javier , Lin, Yi , Paludo, Jonas , Villasboas, José C. , Wang, Yucai , Iqbal, Madiha , Moustafa, Muhamad Alhaj , Murthy, Hemant S. , Hoppe, Bradford S.

Mayo Clinic

Blood Advances | July 19, 2024 | Volume: 8 | Issue: 18 | Pages: 4877-4885

10.1182/bloodadvances.2024013647 | PMID 39028948 Get It

Abstract Unirradiated patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) who undergo anti-CD19 chimeric antigen receptor T-cell therapy (CART) have a predominant localized pattern of relapse, the significance of which is heightened in individuals with limited/localized disease before CART. This study reports on the outcomes of patients with R/R NHL and limited (&lt;5 involved sites) disease bridged with or without radiotherapy. A multicenter retrospective review of 150 patients with R/R NHL who received CART with &lt;5 disease sites before leukapheresis was performed. Bridging treatment, if any, was administered between leukapheresis and CART infusion. Study end points included relapse-free survival (RFS), event-free survival (EFS), and overall survival. Before CART infusion, 48 patients (32%) received bridging radiotherapy (BRT), and 102 (68%) did not. The median follow-up was 21 months. After CART infusion, BRT patients had higher objective response (92% vs 78%; P = .046) and sustained complete response rates (54% vs 33%; P = .015). Local relapse in sites present before CART was lower in the BRT group (21% vs 46%; P = .003). BRT patients had improved 2-year RFS (53% vs 44%; P = .023) and 2-year EFS (37% vs 34%; P = .039) compared with patients who did not receive BRT. The impact of BRT was most prominent in patients who had ≤2 pre-CART involved disease sites, with 2-year RFS of 62% in patients who received BRT compared with 42% in those who did not (P = .002). BRT before CART for patients with limited (&lt;5 involved disease sites) R/R NHL improves response rate, local control, RFS, and EFS without causing significant toxicities.
Radiotherapy for aseptic granulomatous dermatitis: A case report
Sabharwal, Kennedy , Guenzel, Rachael M. , Guenzel, Rachael, Miller, Robert C. , Lester, Scott C.

Mayo Clinic

SAGE Open Medical Case Reports | June 10, 2024 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1177/2050313x241260501 | PMID 38859870 Get It

Granulomatous dermatitis is a common tissue reaction pattern seen in the skin or systematically in various presentations. Granulomatous dermatitis can be subclassified into infectious and non-infectious categories. This article focuses on a patient with non-infectious granulomatous dermatitis followed for many years. Past medical history included bilateral total shoulder arthroplasty complicated by prosthetic joint infections. In its early stages, the axillary rash was painful and had many fluid-filled blisters. Ultimately, the histology of the rash deemed the lesion non-infectious and mostly due to an inflammatory process. Specifically, ionizing radiation was used for this patient. The category of granulomatous processes is broad and there are many subtypes. Other treatment options for non-infectious granulomatous processes may include corticosteroids, phototherapy, and interferon-gamma injections. The differential for granulomatous processes is extensive and treatment should be decided on a case-by-case basis.
Clinical features, molecular findings, and clinical outcomes of follicular dendritic cell sarcoma.
Breen, William G. , Zanwar, Saurabh , Ruan, Gordon , Okuno, Scott H. , Garrity, James, Bennani, Nabila Nora, Abeykoon, Jithma P. , Yi, Dongni , Rech, Karen L. , Lester, Scott C. , Robinson, Steven I. , Siontis, Brittany L. , Kimball, Brittany , Ravindran, Aishwarya , Shah, Meera , Goyal, Gaurav , Go, Ronald S.

Mayo Clinic

Journal of Clinical Oncology | June 3, 2024 | Volume: 42 | Issue: 16_suppl | Pages: e23554-e23554

10.1200/jco.2024.42.16_suppl.e23554 Get It

e23554 Background: Follicular dendritic cell sarcoma (FDCS) is a low-grade neoplasm arising from follicular dendritic cells. Its diagnosis is challenging due to its extreme rarity, and the optimal management remains unknown. Methods: We conducted a retrospective study of FDCS patients (pts) seen at Mayo Clinic, MN since 2018. Time to event analyses were done from the time of diagnosis. Results: Ten pts with FDCS were identified (Table). The median age was 60 years (range, 38-76) and 5 were males. Abdominal pain was the most common presenting symptom (30%) followed by constitutional symptoms, shortness of breath, and vision change. In 3 pts, the diagnosis was incidental. The 2 most common primary locations were abdomen/pelvis (50%) and mediastinum (30%). Six pts (60%) presented with advanced disease and 3 (30%) had Castleman’s disease. Most (60%) had advanced disease. Six pts had Epstein-Barr virus in situ hybridization and all tested negative. Seven pts had next generation sequencing and 5 (83%) had genetic alterations detected with CDKN2A/B alterations being most frequent (3 pts, all with advanced disease). The median follow up was 4.3 years (range, 0.2-13.3). In the 4 patients with localized disease, 3 underwent complete surgical excision resulting in complete remissions (CRs). The one who received radiation had a partial remission (PR). The median time to progression after 1st line treatment was 4 months (all with advanced disease). All 3 pts who died had advanced disease and 2 had CDKN2A/B alterations. Conclusions: In FDCS, localized diseases managed by surgical excision with or without radiation can achieve long term remissions. Advanced diseases generally do not respond to multimodality therapy including immunotherapy but can have disease stabilization with variable survival. CDKN2A/B mutations were common and potentially associated with a worse outcome. Better understanding of the impact of the FDCS mutational landscape on prognosis may provide novel approaches to therapy. [Table: see text]
Impact of Relative Biologic Effectiveness for Proton Therapy for Head and Neck and Skull-Base Tumors: A Technical and Clinical Review
Holtzman, Adam L. , Mohammadi, Homan , Furutani, Keith M. , Koffler, Daniel , McGee, L.A. , Gamez, Mauricio E. , Beltran, Chris , Koffler, Daniel M , McGee, Lisa A, Lester, Scott C. , Beltran, Chris J , Furutani, Keith M , Holtzman, Adam , Routman, David M. , Liang, Xiaoying

Mayo Clinic

Cancers | May 21, 2024 | Volume: 16 | Issue: 11 | Pages: 1947

10.3390/cancers16111947 | PMID 38893068 Get It

Proton therapy has emerged as a crucial tool in the treatment of head and neck and skull-base cancers, offering advantages over photon therapy in terms of decreasing integral dose and reducing acute and late toxicities, such as dysgeusia, feeding tube dependence, xerostomia, secondary malignancies, and neurocognitive dysfunction. Despite its benefits in dose distribution and biological effectiveness, the application of proton therapy is challenged by uncertainties in its relative biological effectiveness (RBE). Overcoming the challenges related to RBE is key to fully realizing proton therapy’s potential, which extends beyond its physical dosimetric properties when compared with photon-based therapies. In this paper, we discuss the clinical significance of RBE within treatment volumes and adjacent serial organs at risk in the management of head and neck and skull-base tumors. We review proton RBE uncertainties and its modeling and explore clinical outcomes. Additionally, we highlight technological advancements and innovations in plan optimization and treatment delivery, including linear energy transfer/RBE optimizations and the development of spot-scanning proton arc therapy. These advancements show promise in harnessing the full capabilities of proton therapy from an academic standpoint, further technological innovations and clinical outcome studies, however, are needed for their integration into routine clinical practice.
Should All Patients With Stage IE Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Receive Antibiotic Eradication Therapy for Helicobacter pylori ?
Laoruangroj, Chonlada , Habermann, Thomas M. , Wang, Yucai , King, Rebecca L. , Lester, Scott C. , Thompson, Carrie A. , Witzig, Thomas E. , Witzig, T.E. , Lester, Scott , Wang, Yucai , Habermann, Thomas

Mayo Clinic

JCO Oncology Practice | May 7, 2024 | Volume: 20 | Issue: 8 | Pages: 1103-1108

10.1200/op.23.00624 | PMID 38713887 Get It

PURPOSE H. pylori eradication therapy (HPE) can lead to tumor regression in H. pylori–positive (HPP) gastric mucosa-associated lymphoid tissue (MALT) lymphoma. However, some patients do not have detectable H. pylori (HP) infection ( H. pylori–negative [HPN]) and the guidelines differ in their initial approach to HPN patients. The National Comprehensive Cancer Network (NCCN) recommends proceeding to radiation therapy, whereas European Society for Medical Oncology suggests HPE for every patient, even those who are HPN. To address this issue, we evaluated the effectiveness of HPE in limited-stage gastric MALT lymphoma. MATERIALS AND METHODS We retrospectively reviewed patients newly diagnosed with stage IE gastric MALT lymphoma between January 2002 and December 2022. The primary outcome was the complete remission (CR) rate defined as no macroscopic findings of lymphoma and negative gastric biopsy at the follow-up gastric endoscopy. RESULTS Fifty-two patients were reviewed, and HP infection was detected in 19 (36.5%) patients—14 by immunostaining, three by serology, and one each by stool antigen and urea breath test. All 19 HPP and eight of the 33 HPN patients received HPE treatment. The CR rate was 63% (12/19) in HPP patients and 13% (1/8) in HPN patients ( P = .033). After a median follow-up of 89.7 months, only two of the 12 HPP patients achieving CR have relapsed; the one HPN patient who received HPE remains in CR at 12+ months. CONCLUSION For limited-stage HPP gastric MALT lymphoma, HPE is an effective and durable first-line treatment and should be used. For HPN patients, the CR rate with HPE is very low in our experience and is thus in support of the NCCN guideline.
Mean Oral Cavity Organ-at-Risk Dose Predicts Opioid Use and Hospitalization during Radiotherapy for Patients with Head and Neck Tumors
Foote, Robert L. , Harmsen, W. Scott, Amundson, A., Gamez, Mauricio E. , Garces, Yolanda I. , Lester, Scott C. , McGee, L.A. , Moore, Eric J. , Wittich, Michelle A. Neben, Patel, Samir H. , Rwigema, Jean‐Claude M. , Abel, Kathryn M. Van , Yin, Linda X. , Muller, Olivia M. , Shiraishi, Satomi , Amundson, Adam C., Carr, Alan B. , Lester, Scott , McGee, Lisa A, Neben Wittich, Michelle A, Yin, Linda X , Van Abel, Kathryn M , Foote, Robert , Shiraishi, Satomi , Daniel, J. , Routman, David M.

Mayo Clinic

Cancers | January 15, 2024 | Volume: 16 | Issue: 2 | Pages: 349

10.3390/cancers16020349 | PMID 38254837 Get It

Background: Approximately 75% of all head and neck cancer patients are treated with radiotherapy (RT). RT to the oral cavity results in acute and late adverse events which can be severe and detrimental to a patient’s quality of life and function. The purpose of this study was to explore associations between RT dose to a defined oral cavity organ-at-risk (OAR) avoidance structure, provider- and patient-reported outcomes (PROs), opioid use, and hospitalization. Methods: This was a retrospective analysis of prospectively obtained outcomes using multivariable modeling. The study included 196 patients treated with RT involving the oral cavity for a head and neck tumor. A defined oral cavity OAR avoidance structure was used in all patients for RT treatment planning. Validated PROs were collected prospectively. Opioid use and hospitalization were abstracted electronically from medical records. Results: Multivariable modeling revealed the mean dose to the oral cavity OAR was significantly associated with opioid use (p = 0.0082) and hospitalization (p = 0.0356) during and within 30 days of completing RT. Conclusions: The findings of this study may be valuable in RT treatment planning for patients with tumors of the head and neck region to reduce the need for opioid use and hospitalization during treatment.
Patterns of progression after immune checkpoint inhibitors for Hodgkin lymphoma: implications for radiation therapy
Burlile, Jessica F. , Frechette, K.M., Breen, William G. , Hwang, Steven R. , Nedved, Adrienne, Harmsen, William S. , Pulsipher, Sydney , Witzig, Thomas E. , Micallef, Ivana N. , Thanarajasingam, Gita , Johnston, Patrick B. , Inwards, David J. , Peterson, Jennifer , Stish, Bradley J. , Rule, William G., Ansell, Stephen M. , Witzig, T.E. , Frechette, Kelsey M, Higgins, Alexandra S, Nedved, Adrienne N, Pulsipher, Sydney D , Hoppe, Bradford S , Bennani, N Nora , Peterson, Jennifer L , Lester, Scott C. , Burlile, Jessica , Hwang, Steven R , Higgins, Alexandra , Hoppe, Bradford S. , Habermann, Thomas M. , Bennani, N. Nora

Mayo Clinic

Blood Advances | January 11, 2024 | Volume: 8 | Issue: 5 | Pages: 1250-1257

10.1182/bloodadvances.2023011533 | PMID 38206755 Get It

Abstract Immune checkpoint inhibitors (ICIs) have demonstrated remarkable response rates in relapsed or refractory Hodgkin lymphoma (HL). Still, most patients eventually progress. Patterns of progression after ICIs are not well described and are essential to defining the role of local therapies in combination with ICIs. We identified patients who received ICIs for HL between 2013 and 2022. Fludeoxyglucose-18 positron emission tomography (FDG-PET) before initiating ICI and at progression on/after ICI were reviewed, and areas of active HL were recorded. An exploratory analysis of treatable progression included patients with ≤5 sites of disease on pre-ICI FDG-PET and progression only at pre-ICI sites. Ninety patients were identified; 69 had complete records, and of these, 32 (52%) had relapsed at ICI initiation, 17 (25%) were refractory, and 16 (23%) received ICI as first-line therapy. Forty-five of 69 patients had ≤5 sites of disease (limited) on pre-ICI FDG-PET. Patients with &gt;5 sites of disease had a higher risk of progression, and every site of disease &gt;5 sites conferred an additional 1.2x higher chance of progression. At a median follow-up of 4.0 years, 41 of 69 patients had progressed on/after ICIs (cumulative incidence 66.4%), and of these, 22 of 41 patients progressed only at pre-ICI sites (cumulative incidence 39.4%). In an exploratory analysis, the cumulative incidence of a treatable progression among 45 patients with limited disease was 34%. The cumulative incidence of any progression among this cohort was 58.9%. More than one-third of patients with limited disease before ICIs experienced progression only at pre-ICI sites of disease. These patients could be candidates for radiation during or after ICIs.